DNA replication licensing is associated with resistance to CDK4/6 inhibitors in ER-positive breast cancer

被引：0
|
作者：
Nanda, Sarmistha
Shea, Martin J.
Schiff, Rachel
Osborne, C. Kent
Rimawi, Mothaffar
Fu, Xiaoyong
机构：
来源：
CANCER RESEARCH | 2023年 / 83卷 / 05期
关键词：
D O I：
10.1158/1538-7445.SABCS22-P2-03-10
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P2-03-10
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Overcoming CDK4/6 inhibitor resistance in ER-positive breast cancer
    Portman, Neil
    Alexandrou, Sarah
    Carson, Emma
    Wang, Shudong
    Lim, Elgene
    Caldon, C. Elizabeth
    ENDOCRINE-RELATED CANCER, 2019, 26 (01) : R15 - R30
  • [2] Combination of ZEN-3694 with CDK4/6 inhibitors reverses acquired resistance to CDK4/6 inhibitors in ER-positive breast cancer
    Kharenko, Olesya A.
    Patel, Reena G.
    Calosing, Cyrus
    van der Horst, Edward H.
    CANCER GENE THERAPY, 2022, 29 (06) : 859 - 869
  • [3] Combination of ZEN-3694 with CDK4/6 inhibitors reverses acquired resistance to CDK4/6 inhibitors in ER-positive breast cancer
    Olesya A. Kharenko
    Reena G. Patel
    Cyrus Calosing
    Edward H. van der Horst
    Cancer Gene Therapy, 2022, 29 : 859 - 869
  • [4] Targeting mTOR to overcome resistance to hormone and CDK4/6 inhibitors in ER-positive breast cancer models
    María Jimena Rodriguez
    María Cecilia Perrone
    Marina Riggio
    Marta Palafox
    Valeria Salinas
    Andrés Elia
    Natali Daiana Salgueiro
    Andrea Eugenia Werbach
    María Paula Marks
    Marcelo A. Kauffman
    Luciano Vellón
    Violeta Serra
    Virginia Novaro
    Scientific Reports, 13
  • [5] Targeting mTOR to overcome resistance to hormone and CDK4/6 inhibitors in ER-positive breast cancer models
    Rodriguez, Maria Jimena
    Perrone, Maria Cecilia
    Riggio, Marina
    Palafox, Marta
    Salinas, Valeria
    Elia, Andres
    Salgueiro, Natali Daiana
    Werbach, Andrea Eugenia
    Marks, Maria Paula
    Kauffman, Marcelo A.
    Vellon, Luciano
    Serra, Violeta
    Novaro, Virginia
    SCIENTIFIC REPORTS, 2023, 13 (01)
  • [6] Combination of ZEN-3694 with CDK4/6 inhibitors reverses resistance in ER-positive breast cancer
    Kharenko, Olesya A.
    Patel, Reena G.
    Calosing, Cyrus
    van der Horst, Edward H.
    CANCER RESEARCH, 2020, 80 (16)
  • [7] Activation of the IFN Signaling Pathway is Associated with Resistance to CDK4/6 Inhibitors and Immune Checkpoint Activation in ER-Positive Breast Cancer
    De Angelis, Carmine
    Fu, Xiaoyong
    Cataldo, Maria Letizia
    Nardone, Agostina
    Pereira, Resel
    Veeraraghavan, Jamunarani
    Nanda, Sarmistha
    Qin, Lanfang
    Sethunath, Vidyalakshmi
    Wang, Tao
    Hilsenbeck, Susan G.
    Benelli, Matteo
    Migliaccio, Ilenia
    Guarducci, Cristina
    Malorni, Luca
    Litchfield, Lacey M.
    Liu, Jiangang
    Donaldson, Joshua
    Selenica, Pier
    Brown, David N.
    Weigelt, Britta
    Reis-Filho, Jorge S.
    Park, Ben H.
    Hurvitz, Sara A.
    Slamon, Dennis J.
    Rimawi, Mothaffar F.
    Jansen, Valerie M.
    Jeselsohn, Rinath
    Osborne, C. Kent
    Schiff, Rachel
    CLINICAL CANCER RESEARCH, 2021, 27 (17) : 4870 - 4882
  • [8] PALBOCICLIB: CDK4/6 INHIBITION IN THE TREATMENT OF ER-POSITIVE BREAST CANCER
    Owsley, J.
    Jimeno, A.
    Diamond, J. R.
    DRUGS OF TODAY, 2016, 52 (02) : 119 - 129
  • [9] Mechanistic exploration of combined CDK4/6 and ER inhibition in ER-positive breast cancer
    Lee, Nathan V.
    Yuan, Jing
    Eisele, Koleen
    Cao, Joan Q.
    Painter, Cory L.
    Chionis, John
    Liu, Chaoting
    Shields, David J.
    Kan, Julie L. C.
    Arndt, Kim
    VanArsdale, Todd
    CANCER RESEARCH, 2014, 74 (19)
  • [10] Patterns of genomic alterations in ER-positive advanced breast cancer patients treated with CDK4/6 inhibitors
    Cruz, Marcelo R.
    Limentani, Kimberly
    Taxter, Timothy
    Santa-Maria, Cesar A.
    Behdad, Amir
    Gradishar, William J.
    Nagy, Rebecca J.
    Cristofanilli, Massimo
    CANCER RESEARCH, 2018, 78 (04)
12345